Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Business & Wealth
Market Voices
Ksenia Gerey
Ksenia Gerey

Vir Biotechnology unveils new clinical data on oral therapies for chronic Hepatitis Delta

Vir Biotechnology unveils new clinical data on oral therapies for chronic Hepatitis Delta
Vir to present Hepatitis Delta data

Vir Biotechnology announced it will present expanded Phase 2 SOLSTICE clinical trial results evaluating its investigational drugs elebsiran and tobevibart for chronic Hepatitis Delta.

The presentations will take place at AASLD’s annual meeting in Denver, focusing on two oral therapies aimed at addressing the unmet medical needs of patients with Hepatitis Delta. Additional details about the study outcomes will be shared during the conference.

Vir Biotechnology recently named Aziz Sawaf as executive vice president and chief financial officer, assigning him oversight of finance, operations, IT, and investor relations. The appointment was announced earlier this year. The company continues to advance its clinical pipeline alongside leadership changes.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

From PlayStation to crypto: Why Sony is building its own blockchain
  • By Ksenia Gerey
  • 7 hours ago
From PlayStation to crypto: Why Sony is building its own blockchain
Editors' Picks
Google loses billions: What’s behind Alphabet’s stock crash?
  • By Oleg Tkachenko
  • 10 hours ago
Google loses billions: What’s behind Alphabet’s stock crash?
Editors' Picks
The end of Bitcoin’s growth era: Why prominent investors doubt its future
  • By Olena Litvinenko
  • Yesterday
The end of Bitcoin’s growth era: Why prominent investors doubt its future
Editors' Picks
All Editors' Top Picks

Latest Vir Biotechnology News

Vir Biotechnology advances dual-masked TCE pipeline targeting difficult-to-treat solid tumors
  • By Ksenia Gerey
  • 22.10.2026
Vir Biotechnology advances dual-masked TCE pipeline targeting difficult-to-treat solid tumors
Companies
#Vir Biotechnology
Vir Biotechnology to hold investor call on Q3 2026 performance
  • By Hanna Syniavska
  • 21.10.2026
Vir Biotechnology to hold investor call on Q3 2026 performance
Companies
#Vir Biotechnology
Vir Biotechnology advances Phase 3 ECLIPSE program for Hepatitis Delta treatment
  • By Eugene Komchuk
  • 16.10.2026
Vir Biotechnology advances Phase 3 ECLIPSE program for Hepatitis Delta treatment
Companies
#Vir Biotechnology
All Vir Biotechnology News
  • Ksenia Gerey
  • 7 hours ago
From PlayStation to crypto: Why Sony is building its own blockchain
  • Oleg Tkachenko
  • 10 hours ago
Google loses billions: What’s behind Alphabet’s stock crash?
  • Olena Litvinenko
  • Yesterday
The end of Bitcoin’s growth era: Why prominent investors doubt its future
  • Eugene Komchuk
  • Yesterday
WeFi CEO: Banks are overstating the threat from stablecoins
  • Dmytro Kharkov
  • Yesterday
HSBC’s warning signs point to a bigger risk for global banks
  • Yaroslav Dmytrenko
  • 11 min ago
Fed decision to hold rates raises questions, Nick Timiraos notes
  • Mikhail Vnuchkov
  • 30 min ago
Jeremy Horpedahl: Middle-quintile families spend less on TV and video than in recent past
  • Igor Krasulya
  • 30 min ago
First ETFs deploy U.S. company dividends into Bitcoin, Steven Lubka notes
  • Oksana Koneva
  • 30 min ago
Investment of $1.6B CAD in Cohere to create 1,000 jobs in Canada, Evan Solomon says
  • Daria Chernytska
  • 30 min ago
Ford government deepens deficit and emphasizes saving money, Colin D'Mello notes
Top News
  • Hanna Syniavska
  • 3 hours ago
ECB leaves interest rates at 2.5% as inflation pressures persist
ECB leaves interest rates at 2.5% as inflation pressures persist
  • Eugene Komchuk
  • 4 hours ago
Christine Lagarde announces early resignation as ECB president
Christine Lagarde announces early resignation as ECB president
  • Olga Shendetskaya
  • 5 hours ago
Brent drops below $110 as Middle East peace talks ease supply concerns
Brent drops below $110 as Middle East peace talks ease supply concerns
  • Andrey Mastykin
  • 5 hours ago
Nasdaq futures decline as Alphabet sparks tech selloff
Nasdaq futures decline as Alphabet sparks tech selloff
  • Olga Shendetskaya
  • 8 hours ago
ECB set to hold rates despite inflation and French bond market turmoil
ECB set to hold rates despite inflation and French bond market turmoil
Live News
  • Anton Kharitonov
  • Now
EUR/USD remains in a strong downtrend as ECB decision approaches
  • Jose Antonio Gastelum
  • Now
Cardano Foundation expands role in Swiss tokenized securities market
  • Mykhailo Ihnatenko
  • Now
Nvidia stock faces $210 risk as Alphabet earnings shake AI sentiment
  • Pavlo Kot
  • Now
Visa stablecoin settlement volume surges tenfold to $25 billion
  • Mykhailo Ihnatenko
  • Now
Ethereum price faces $2,200 risk as early holder activity and ETF outflows weigh
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers